Salim Syed
Stock Analyst at Mizuho
(1.92)
# 3,047
Out of 4,876 analysts
81
Total ratings
36.92%
Success rate
-8.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTX Nkarta | Maintains: Outperform | $16 → $14 | $1.66 | +743.37% | 8 | Jun 10, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $103 → $84 | $33.16 | +153.32% | 7 | May 29, 2025 | |
| BIIB Biogen | Maintains: Outperform | $207 → $169 | $126.08 | +34.04% | 16 | May 7, 2025 | |
| AMGN Amgen | Maintains: Neutral | $235 → $280 | $277.13 | +1.04% | 8 | May 7, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $100 → $117 | $110.67 | +5.72% | 7 | May 5, 2025 | |
| WVE Wave Life Sciences | Maintains: Outperform | $19 → $22 | $6.67 | +229.84% | 5 | Nov 21, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $32.58 | +400.31% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $7.96 | +126.13% | 4 | Aug 16, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $34 | $20.65 | +64.69% | 1 | Apr 9, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $99 | $47.49 | +108.46% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $53 | $44.86 | +18.15% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $6 | $0.77 | +677.81% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $0.74 | +2,726.00% | 5 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $168 → $36 | $17.21 | +109.18% | 1 | Nov 16, 2022 |
Nkarta
Jun 10, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $1.66
Upside: +743.37%
Cytokinetics
May 29, 2025
Maintains: Outperform
Price Target: $103 → $84
Current: $33.16
Upside: +153.32%
Biogen
May 7, 2025
Maintains: Outperform
Price Target: $207 → $169
Current: $126.08
Upside: +34.04%
Amgen
May 7, 2025
Maintains: Neutral
Price Target: $235 → $280
Current: $277.13
Upside: +1.04%
Gilead Sciences
May 5, 2025
Maintains: Outperform
Price Target: $100 → $117
Current: $110.67
Upside: +5.72%
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19 → $22
Current: $6.67
Upside: +229.84%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $32.58
Upside: +400.31%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $7.96
Upside: +126.13%
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $20.65
Upside: +64.69%
CRISPR Therapeutics AG
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $47.49
Upside: +108.46%
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $44.86
Upside: +18.15%
Mar 28, 2023
Maintains: Buy
Price Target: $12 → $6
Current: $0.77
Upside: +677.81%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $0.74
Upside: +2,726.00%
Nov 16, 2022
Maintains: Buy
Price Target: $168 → $36
Current: $17.21
Upside: +109.18%